Cargando…

Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease

Patients with sickle cell disease (SCD) are at increased risk for invasive pneumococcal disease because of splenic dysfunction. To mitigate this risk, patients are protected with prophylactic penicillin until completion of pneumococcal vaccination series. The objective of this study was to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahim, Mahvish Q., Arends, Alexandria M., Jacob, Seethal A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Online Articles: Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728750/ https://www.ncbi.nlm.nih.gov/pubmed/33974588 http://dx.doi.org/10.1097/MPH.0000000000002187

Ejemplares similares

Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
por: Adamkiewicz, Thomas V., et al.
Publicado: (2023)

Immunogenicity of pneumococcal vaccination in a patient with sickle hemoglobinopathy: a case report
por: Clay, E Leila Jerome, et al.
Publicado: (2015)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Pediatric hematology/oncology physician and nurse practitioner attitudes towards the COVID-19 vaccines: A qualitative study
por: Miller, Meagan E., et al.
Publicado: (2022)

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

153. AYA Subspecialty Patient and Parent Views on COVID-19 Vaccination
por: Hardman, Sara, et al.
Publicado: (2022)

Impact of Pneumococcal Conjugate Vaccine on Vaccine Serotype–Specific Pneumonia
por: Klugman, Keith P, et al.
Publicado: (2020)

Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
por: Ryman, Josiah, et al.
Publicado: (2022)

Understanding the roots of mistrust in medicine: Learning from the example of sickle cell disease [Image: see text]
por: LaMotte, Julia E., et al.
Publicado: (2022)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Caregiver experiences with accessing sickle cell care and the use of telemedicine
por: Jacob, Seethal A., et al.
Publicado: (2022)

Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease
por: Ingels, Helene A. S., et al.
Publicado: (2018)

Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13(®)) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS
por: Makenga, Geofrey, et al.
Publicado: (2021)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Incidence of Acute Chest Syndrome in Children With Sickle Cell Disease Following Implementation of the 13-Valent Pneumococcal Conjugate Vaccine in France
por: Assad, Zein, et al.
Publicado: (2022)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
por: Mackenzie, Grant A., et al.
Publicado: (2022)

Understanding caregiver burden with accessing sickle cell care in the Midwest and their perspective on telemedicine
por: Jacob, Seethal A., et al.
Publicado: (2023)

Nasopharyngeal Carriage of Methicillin-Resistant Staphylococcus aureus (MRSA) among Sickle Cell Disease (SCD) Children in the Pneumococcal Conjugate Vaccine Era
por: Dayie, Nicholas T. K. D., et al.
Publicado: (2021)

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals
por: Nunes, Marta C., et al.
Publicado: (2012)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Immunogenicity
por: Deloria Knoll, Maria, et al.
Publicado: (2014)

Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets
por: Aceil, Javid, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Nasopharyngeal Carriage and Antibiogram of Pneumococcal and Other Bacterial Pathogens from Children with Sickle Cell Disease in Tanzania
por: Mutagonda, Ritah F, et al.
Publicado: (2022)

Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
por: Teles, Mayan S, et al.
Publicado: (2022)

Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children
por: Fortunato, Francesca, et al.
Publicado: (2015)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
por: van den Biggelaar, Anita H. J., et al.
Publicado: (2017)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults
por: Chichili, Gurunadh, et al.
Publicado: (2020)

Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia
por: Sheehan, Vivien A., et al.
Publicado: (2022)

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
por: Pomat, William S., et al.
Publicado: (2013)

COVID-19 in Adults with Sickle Cell Disease: Data from Cerner Real-World Database
por: Guarino, Stephanie H, et al.
Publicado: (2022)

PB2514: IMMUNOGENICITY OF ANTI-SARS-COV-2 VACCINES IN PATIENTS WITH SEVERE SICKLE CELL DISEASE
por: Meunier, Benoit, et al.
Publicado: (2023)

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
por: Ladhani, Shamez N., et al.
Publicado: (2013)

Pneumococcal disease and use of pneumococcal vaccines in Taiwan
por: Wei, Sung-Hsi, et al.
Publicado: (2015)

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
por: Thisyakorn, Usa, et al.
Publicado: (2014)

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children
por: Orami, Tilda, et al.
Publicado: (2020)

Antibody response to pneumococcal vaccination in children with chronic or recurrent rhinosinusitis
por: Baek, Ji Hyeon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kju62oti8gd6g95ip34msdvo6u